# A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

> **NCT01085422** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 35 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ABT-888
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT01085422
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085422, "A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01085422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*